Certriad NDA gets complete response

FDA issued a complete response letter for an NDA for Certriad rosuvastatin/fenofibric acid from Abbott Laboratories (NYSE:ABT) and AstraZeneca plc (LSE:AZN; NYSE:AZN) to treat mixed dyslipidemia. The ...